| Document |
Document Title |
|
WO/2024/062348A1 |
Hydroalcoholic single phase gel compositions comprising diclofenac or a pharmaceutically acceptable salt of diclofenac are disclosed. The compositions are single phase compositions, and don't contain a lipophilic phase. The compositions ...
|
|
WO/2024/062986A1 |
Provided is a powder composition that can be made into a foamy food product exhibiting a masking effect and being highly dispersible in an aqueous solvent. The powder composition is to be made into a foamy food product by mixing with wat...
|
|
WO/2024/063700A1 |
An oral formulation comprising a diaminophenothiazine compound and a mucoadhesive gastro-retentive platform is disclosed, as well as veterinary uses thereof in treatment and or prevention of diseases such as avian wasting diseases. Metho...
|
|
WO/2024/064743A2 |
The disclosure relates to recombinant nucleic acids comprising polynucleotides encoding zinc- finger DNA binding domains (ZF-DBDs), and vectors comprising the same. In some embodiments, the encoded ZF-DBDs are capable of targeting a GATA...
|
|
WO/2024/061371A1 |
Provided is a small-molecule steroid synthetase inhibitor. Further provided is use of the steroid synthetase inhibitors.
|
|
WO/2024/061340A1 |
This disclosure provides compounds of Formula 1 or 8, compositions comprising the same, and methods of using the same, including uses in modulating NAMPT and treating various diseases and conditions that are responsive to NAMPT activation.
|
|
WO/2024/063566A1 |
A pharmaceutical composition for the destruction of tumor blood vessels, according to an exemplary embodiment, may comprise alkaline 5-fluorouracil and glucose. For example, the composition comprises glucose and thus exerts a synergistic...
|
|
WO/2024/061202A1 |
The present disclosure relates to a double-stranded ribonucleic acid (RNA) for inhibiting HMGB1 gene expression, and a modifier, conjugate and use thereof. Specifically, the present disclosure relates to a double-stranded RNA for inhibit...
|
|
WO/2024/063734A1 |
The present invention relates to a film coated tablet comprising mirabegron, polyethylene oxide and at least one pharmaceutically acceptable excipient wherein the weight ratio of polyethylene oxide to mirabegron ranges from 1 :1 to 4:1 s...
|
|
WO/2024/061365A1 |
Provided are a compound represented by formula (I), or a tautomer, a cis-trans isomer, a mesomer, a racemate, an enantiomer, a diastereomer, or an atropisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt, a s...
|
|
WO/2024/064147A1 |
This document relates to methods and materials for treating congenital disorders of glycosylation (CDG; e.g., a phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG)). For example, this document provides methods and materi...
|
|
WO/2024/062713A1 |
The present invention relates to a gel-forming material comprising at least one component A selected from the group consisting of modified hyaluronic acid having an amino group and an average molecular weight of 10,000 or more and a salt...
|
|
WO/2024/061366A1 |
Disclosed in the present application are a small molecule compound having a phosphorylated aryl structure, and the use thereof. The compound and a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof provided in the...
|
|
WO/2024/064328A1 |
Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).
|
|
WO/2024/062423A1 |
The invention provides an oromucosal film composition comprising: a therapeutically effective amount of one or more active pharmaceutical ingredients selected from the group consisting of fluticasone, liraglutide, glucagone, midazolam, d...
|
|
WO/2024/059951A1 |
This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are m...
|
|
WO/2024/063568A1 |
The present invention relates to combination therapy for the treatment of type 2 diabetes, and the combination therapy may achieve clinically significant effects in patients with type 2 diabetes whose blood glucose is not adequately cont...
|
|
WO/2024/061354A1 |
The present invention provides an interfering RNA targeting TOP1 gene. The interfering RNA can reduce the expression of TOP1, thereby treating a disease related to TOP1 expression. The present invention further provides a lipid nanoparti...
|
|
WO/2024/064646A1 |
Provided herein are salts of and solid forms comprising free base or salts of (S)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)
piperidine-2,6-dione. Pharmaceutical compositions comprising such salts and solid ...
|
|
WO/2024/064858A2 |
Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of methyl CpG binding protein 2 (MECP2) RNA in a cell or animal, and in certain instances reducing the amount of MECP2 protei...
|
|
WO/2024/061257A1 |
Disclosed are a polycyclic N-heterocyclic ketone compound and use thereof, and specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2024/064883A2 |
The present disclosure provides therapeutic combinations comprising (i) a ubiquitinspecific- processing protease 1 (USP1) inhibitor and (ii) PARP1-selective inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous so...
|
|
WO/2024/064335A1 |
The disclosure provides naphthyl-substituted pyranopyrimidinones and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras activity and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2024/058926A1 |
Disclosed are methods of treating phenylketonuria, comprising administering to a patient in need thereof an effective amount of the following compound: Formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/058240A1 |
The present invention addresses the problem of clarifying what type of a curcumin preparation is effective for various symptoms of common cold among various types of curcumin preparations. The present invention relates to a common cold...
|
|
WO/2024/059204A1 |
Negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatr...
|
|
WO/2024/056099A1 |
Provided is use of a compound of formula I, formula I', or formula I", and a tautomer, a stereoisomer, or a pharmaceutically acceptable salt thereof as an METTL3 inhibitor. The compound can be used for treating a condition and a disease ...
|
|
WO/2024/056079A1 |
The present invention relates to a polymorphic form of a nepicastat acid addition salt, a preparation method therefor and a use thereof. The acid addition salt is selected from hydrochloride, sulfate, phosphate, mesylate, benzenesulfonat...
|
|
WO/2024/055795A1 |
Disclosed herein are a medicine and food dual-purpose composition capable of resisting blue light damage to retina, a preparation method therefor, and use thereof, and belongs to the technical field of medicine and food dual purposes. Th...
|
|
WO/2024/057192A1 |
Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psilocybin or a metabolite thereof, and related uses. The disclosure in some aspects also relates to methods for identifyi...
|
|
WO/2024/059609A1 |
The present disclosure relates to pharmaceutical forms of a CD73 inhibitor, polymorphic forms of the pharmaceutical forms, pharmaceutical compositions comprising the pharmaceutical forms, and methods of treating subjects having cancer by...
|
|
WO/2024/059559A1 |
The invention provides isothiazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or co...
|
|
WO/2024/057013A1 |
Disclosed are compounds, compositions and methods for treating disease, syndromes, conditions and disorders that are affected by the modulation of NLRP3 and/or the NLRP3 inflammasome. Such compounds are represented by Formula (I), wherei...
|
|
WO/2024/059873A2 |
Nucleic acid products and compositions are provided, together with methods for their use, to modulate, in particular, interfere with or inhibit CFB and C5 gene expression.
|
|
WO/2024/058527A1 |
The present invention relates to a pharmaceutical composition for preventing or treating hearing loss comprising esomeprazole or dexlansoprazole as an active ingredient. As the effects of esomeprazole or dexlansoprazole on protecting hai...
|
|
WO/2024/056568A1 |
The present invention relates to a composition comprising cysteamine, azabenzene-4-carboxamide and glycolic acid. The present invention also relates to the cosmetic use thereof for inhibiting, reducing or preventing skin pigmentation and...
|
|
WO/2024/056016A1 |
The present invention relates to a free base crystal form of a polycyclic compound of a nitrogen-containing heterocycle, and a preparation method therefor. Specifically, the present invention provides a free base crystal form of a compou...
|
|
WO/2024/055879A1 |
Provided are a class of fused bicyclic compounds, a method for preparing same, and use thereof. Particularly, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymo...
|
|
WO/2024/059778A2 |
Methods of modulating expression and / or secretion of at least one of IRG1, TNFα, IL-6, IL-1b, itaconate, CXCL-10, IRAK4, major histocompatibility complex II (MHC II), and NFκB in a subject and method of treating or preventing a disea...
|
|
WO/2024/059317A1 |
Provided are YAP/TAZ-TEAD oncoproteins inhibitors of Formula (I), or a stereoisomer, and/or a pharmaceutically acceptable salt, and/or solvate thereof, pharmaceutical compositions thereof, and methods of treatment.
|
|
WO/2024/059618A2 |
Provided herein are recombinant nucleic acids that reduce expression of TGFBR1 and/or TGFBR2 and cells comprising such recombinant nucleic acids. Also provided are methods of making and using such cells.
|
|
WO/2024/058617A1 |
The present invention relates to an antiviral use of a fused heteroaryl derivative. A fused heteroaryl derivative according to the present invention exhibits excellent inhibitory activity against ANO6, and thus can be effectively used as...
|
|
WO/2024/059142A1 |
Solid dispersion comprising 20-40 wt% of etrumadenant and 60-80 wt% of a polymer selected from HPMCAS, PVP-PA, CAP, HPMC E3, HPMCP, PVP and polyvinyl caprolactam-polyvinyl acetate-PEG graft copolymer. A process for preparing said composi...
|
|
WO/2024/058975A1 |
The present disclosure provides compounds, compositions, and methods, wherein the compounds include a modified cholic acid or a cholic acid component and at least a second component in which the second component is conjugated to the modi...
|
|
WO/2024/057021A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
|
WO/2024/056019A1 |
Disclosed herein are bicyclic compound derivatives used as inhibitors of cyclin-dependent kinases. Disclosed herein is the use of these inhibitors for inhibiting cyclin-dependent kinases, and the use of such compounds for treating cancer.
|
|
WO/2024/059247A2 |
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance compr...
|
|
WO/2024/059052A1 |
A composition, comprising: two or more oligosaccharides selected from th egroup consisting of 2-fucosyllactose (2FL), 3-fucosyllactose (3FL), and 3-sialyllactose (3SL) is disclosed.
|
|
WO/2024/056090A1 |
Disclosed are a pyrrolopyrimidine derivative as an RSK inhibitor and use thereof. Specifically, disclosed are a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, and use of the compound...
|
|
WO/2024/059563A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
|
